- Home
- NRGV vs IGMS Comparison
NRGV vs IGMS Comparison
Compare NRGV & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- IGMS
- Stock Information
- Founded
- NRGV 2017
- IGMS 1993
- Country
- NRGV United States
- IGMS United States
- Employees
- NRGV N/A
- IGMS N/A
- Industry
- NRGV Industrial Machinery/Components
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- IGMS Health Care
- Exchange
- NRGV Nasdaq
- IGMS Nasdaq
- Market Cap
- NRGV 102.3M
- IGMS 82.1M
- IPO Year
- NRGV N/A
- IGMS 2019
- Fundamental
- Price
- NRGV $0.86
- IGMS $1.36
- Analyst Decision
- NRGV Buy
- IGMS Hold
- Analyst Count
- NRGV 3
- IGMS 8
- Target Price
- NRGV $1.58
- IGMS $6.00
- AVG Volume (30 Days)
- NRGV 2.1M
- IGMS 1.1M
- Earning Date
- NRGV 08-05-2025
- IGMS 08-13-2025
- Dividend Yield
- NRGV N/A
- IGMS N/A
- EPS Growth
- NRGV N/A
- IGMS N/A
- EPS
- NRGV N/A
- IGMS N/A
- Revenue
- NRGV $46,974,000.00
- IGMS $2,681,000.00
- Revenue This Year
- NRGV $362.17
- IGMS $134.30
- Revenue Next Year
- NRGV $48.19
- IGMS $22.37
- P/E Ratio
- NRGV N/A
- IGMS N/A
- Revenue Growth
- NRGV N/A
- IGMS 27.36
- 52 Week Low
- NRGV $0.60
- IGMS $0.92
- 52 Week High
- NRGV $2.70
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- NRGV 52.80
- IGMS 59.58
- Support Level
- NRGV $0.65
- IGMS $1.12
- Resistance Level
- NRGV $0.74
- IGMS $1.39
- Average True Range (ATR)
- NRGV 0.07
- IGMS 0.08
- MACD
- NRGV 0.00
- IGMS 0.01
- Stochastic Oscillator
- NRGV 73.80
- IGMS 83.87
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.